Last reviewed · How we verify
Full course of PD-1/PD-L1 blockades
Full course of PD-1/PD-L1 blockades is a PD-1/PD-L1 inhibitor Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Advanced or metastatic solid tumors (specific indications under investigation in phase 3 trials).
PD-1/PD-L1 blockade releases the brakes on the immune system by inhibiting checkpoint proteins that cancer cells use to evade T-cell attack, thereby restoring anti-tumor immunity.
PD-1/PD-L1 blockade releases the brakes on the immune system by inhibiting checkpoint proteins that cancer cells use to evade T-cell attack, thereby restoring anti-tumor immunity. Used for Advanced or metastatic solid tumors (specific indications under investigation in phase 3 trials).
At a glance
| Generic name | Full course of PD-1/PD-L1 blockades |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-1 and PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PD-1 (programmed death receptor 1) and PD-L1 (programmed death ligand 1) are immune checkpoint proteins that suppress T-cell function. Blocking these interactions prevents tumor cells from inactivating cytotoxic T lymphocytes, allowing the immune system to recognize and eliminate cancer cells. This approach has demonstrated efficacy across multiple solid and hematologic malignancies.
Approved indications
- Advanced or metastatic solid tumors (specific indications under investigation in phase 3 trials)
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
- Rash
Key clinical trials
- Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy. (PHASE3)
- Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Full course of PD-1/PD-L1 blockades CI brief — competitive landscape report
- Full course of PD-1/PD-L1 blockades updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about Full course of PD-1/PD-L1 blockades
What is Full course of PD-1/PD-L1 blockades?
How does Full course of PD-1/PD-L1 blockades work?
What is Full course of PD-1/PD-L1 blockades used for?
Who makes Full course of PD-1/PD-L1 blockades?
What drug class is Full course of PD-1/PD-L1 blockades in?
What development phase is Full course of PD-1/PD-L1 blockades in?
What are the side effects of Full course of PD-1/PD-L1 blockades?
What does Full course of PD-1/PD-L1 blockades target?
Related
- Drug class: All PD-1/PD-L1 inhibitor drugs
- Target: All drugs targeting PD-1 and PD-L1
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced or metastatic solid tumors (specific indications under investigation in phase 3 trials)
- Compare: Full course of PD-1/PD-L1 blockades vs similar drugs
- Pricing: Full course of PD-1/PD-L1 blockades cost, discount & access